Back to Search
Start Over
Table S4 from Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Clinical characteristics in ALK-rearranged NSCLC based on integrin β3 immunohistochemistry score
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....20ed76b0f335255754dc9e2f1801b89c
- Full Text :
- https://doi.org/10.1158/1078-0432.22469514